Antigen-specific immunotherapy combined with a regenerative drug in the treatment of experimental type 1 diabetes

Type 1 diabetes is an autoimmune disease caused by the destruction of the insulin-producing β-cells. To revert type 1 diabetes, the suppression of the autoimmune attack should be combined with a β-cell replacement strategy. It has been previously demonstrated that liraglutide, a glucagon-like peptid...

Descripción completa

Detalles Bibliográficos
Autores principales: Villalba, Adrian, Rodriguez-Fernandez, Silvia, Perna-Barrull, David, Ampudia, Rosa-Maria, Gomez-Muñoz, Laia, Pujol-Autonell, Irma, Aguilera, Eva, Risueño, Ruth M., Cano-Sarabia, Mary, Maspoch, Daniel, Vázquez, Federico, Vives-Pi, Marta
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2020
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7609712/
https://www.ncbi.nlm.nih.gov/pubmed/33144616
http://dx.doi.org/10.1038/s41598-020-76041-1

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7609712/
https://www.ncbi.nlm.nih.gov/pubmed/33144616
http://dx.doi.org/10.1038/s41598-020-76041-1

Ejemplares similares